Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPY4R | P50391 | 11/20 | 0.32 |
| ▸ | NPY1R | P25929 | 7/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.32 |
| ▸ | NPY2R | P49146 | 3/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26329010 | 0.86 | MEN1 (0.33) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL20792037 | 0.81 | MEN1 (0.37) | MEN1CYP1A2KMT2ASMN1; SMN2ALOX15 | |
| SCHEMBL13769032 | 0.81 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL14632143 | 0.81 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL15478607 | 0.81 | NPY4R (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL19187427 | 0.80 | MEN1 (0.36) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL26429269 | 0.78 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL8120411 | 0.78 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL1388278 | 0.78 | NPY4R (0.41) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R | |
| SCHEMBL93473 | 0.77 | FOLH1 (0.38) | MEN1CYP1A2KMT2ASMN1; SMN2NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | MEN1 3337/4885CYP1A2 59/4885KMT2A 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.